Vascular Medicine

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Charles P. Vega, MD We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A collaborative approach to addressing residual cardiovascular risk across a variety of risk factors that goes beyond LDL-C-lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients will benefit from a review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.

Host: Craig I. Coleman, PharmD, FASHP Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

Host: Craig I. Coleman, PharmD, FASHP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

Host: Craig I. Coleman, PharmD, FASHP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

Host: Deborah Siegal, MD, MSc, FRCPC The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

Host: Jan Beyer-Westendorf, MD, PhD The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Emily Carroll, JD, MSW The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.

Host: Andrew Wilner, MD, FACP, FAAN Guest: William W. Li, MD As the number of new COVID-19 infections continues to decrease and the United States begins to open back up, it’s important to note that there are patients who have survived COVID-19 but are still suffering. The newly coined term “COVID long-haulers” refers to those patients who continue to have symptoms even after the acute infection is resolved. Joining Dr. Andrew Wilner to share what we know so far about COVID long-haulers and how we can help them is vascular biologist Dr. William Li.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Adam Olsen, MS, PA-C Millions of patients are treated with anticoagulants, and many more are treated with antiplatelet therapy. But when those therapies overlap with GI bleeding, what do you need to know so that your patients don’t experience any problematic health outcomes? Dr. Peter Buch is discussing this topic with physician assistant Mr. Adam Olsen, who’s the Department Chair and Program Director for the Master of Physician Assistant Studies Program at Sacred Heart University in Stamford, Connecticut.

Host: Jerome Lisk, MD Guest: Ilan Wittstein, MD How do you mend a broken heart? Dr. Ilan Wittstein, the Director of the Advanced Heart Failure Fellowship and Assistant Professor of Medicine at Johns Hopkins School of Medicine, joins Dr. Jerome Lisk to discuss broken heart syndrome and some of its challenges.

Host: Jerome Lisk, MD Guest: Ilan Wittstein, MD With no standard criteria available, how do we detect broken heart syndrome in our patients? Dr. Ilan Wittstein, the Director of the Advanced Heart Failure Fellowship and Assistant Professor of Medicine at Johns Hopkins School of Medicine, shares what we should be looking for.

Host: Matthew J. Sorrentino, MD, FACC, FASH Guest: Salim S. Virani, MD, PhD, FACC, FAHA, FASPC What is the leading cause of death worldwide? Dr. Matthew Sorrentino sits down with Dr. Salim Virani, who's a professor of medicine at Baylor College of Medicine in Houston, Texas, and the Cardiovascular Disease Fellowship director at Baylor, to discuss how the COVID-19 pandemic has impacted cardiovascular disease globally.

Host: Matthew J. Sorrentino, MD, FACC, FASH Guest: C. Michael Gibson, MD, FSCAI Following a major cardiovascular event, what interventional strategies should we be considering? Dr. Matthew Sorrentino joins Dr. Michael Gibson, a professor of medicine and cardiology at the Beth Israel Deaconess Medical Center at Harvard Medical School in Boston, Massachusetts to discuss antiplatelet and anticoagulation strategies for patients with cardiovascular disease.

Host: Matthew J. Sorrentino, MD, FACC, FASH Guest: Eliot Brinton, MD, FAHA, FNLA What do we need to know about the impact of triglyceride levels? Dr. Elliot Brinton, President at the Utah Lipid Center in Salt Lake City briefly dives into the impact that triglycerides have on our endothelial cells and LDL cholesterol.

Host: Matthew J. Sorrentino, MD, FACC, FASH Guest: Alan S. Brown, MD, FACC, FAHA, FNLA With an explosion in new medications to treat diabetes, Heart Matters hosts Dr. Matthew Sorrentino and Dr. Alan Brown sit down to discuss the cardiovascular risk benefits of these new diabetes treatments and how cardiologists can improve patient care.

Host: Matthew J. Sorrentino, MD, FACC, FASH Guest: Eliot Brinton, MD, FAHA, FNLA One of the leading causes of death in the US, cardiovascular disease risk-reduction has neglected triglycerides. To explain why that is, Dr. Matthew Sorrentino discusses approaches to take when reducing the risk of cardiovascular disease with expert guest, Dr. Elliot Brinton, president of the Utah Lipid Center in Salt Lake City.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Arun Sharma, PhD Can low gravity and space flight impact our cardiac function? Dr. Arun Sharma, a stem cell biologist at Cedars-Sinai Medical Center in California, joins Dr. Alan Brown to discuss the impact of outer space on the heart.